Extensive depth of experience comes with new leaders – Chief Operating Officer, Chief Financial Officer, Chief Administrative Officer and Chief Science and Strategy Officer Marlton, NJ, Sept. 24, 2024 (Korea Bizwire) – Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments: [...]
Opportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and Miami, FL. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Jackson Health System, one of the nation’s largest public health systems in [...]
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder2,3 Data presented at the European [...]
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 [...]
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPs New data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified New ADVANCE survey findings highlight key patient-reported [...]
Duke-NUS Medical School’s Dr. Linfa Wang Awarded GVN’s 2024 Robert C. Gallo Award for Scientific Excellence and Leadership DURBAN, South Africa, Sept. 18, 2024 (Korea Bizwire) – The Global Virus Network concluded its annual meeting of closed scientific sessions held 16-18 September 2024 with a press conference. Co-hosted by the Centre for the AIDS Programme of Research in South Africa [...]
SPRING, Texas, Sept. 18, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration with its clinical stage experimental therapeutic RXR agonist compound IRX4204. The presentation titled “The highly potent and selective third generation RXR nuclear receptor agonist compound IRX4204 has potential [...]
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery – including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design [...]
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms VANCOUVER, British Columbia, Sept. 18, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat cancers and [...]
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo. The FIBRONEER™-IPF trial is the largest trial in idiopathic pulmonary fibrosis (IPF) conducted to date. Patients were recruited in over 330 sites and in [...]